Socio-economic status and the therapeutic effectiveness of antihypertensive treatment - The design of the LEO study

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1987-1995

  Schmidt, André C ^a   Bramlage, P ^b   Lichtenthal, A ^c   Eckert, M ^d   Scholze, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Berlin Chemie AG   (Germany)

^d SIMW GmbH   (Germany)

Author keywords

Compliance; Effectiveness; Hypertension; Persistence; Socio economic class; Study design

Indexed keywords

HYDROCHLOROTHIAZIDE; OLMESARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; SOCIAL STATUS; SOCIOECONOMICS;

ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; MALE; PATIENT COMPLIANCE; RESEARCH DESIGN; SOCIAL CLASS;

EID: 34548130723     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X226078     Document Type: Article

References (46)

1. Thamm M. Blutdruck in Deutschland - aktueller Status und Trends. Gesundheitswesen 1999;61(Spec No):S90-S93
2. Sharma AM, Wittchen HU, Kirch W, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004;22:479-86
3. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. J Am Med Assoc 2003;289:2363-9
4. ESH/ESC. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
5. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. J Am Med Assoc 2003;289:2534-44
6. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-7
7. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
8. Takala J, Kumpusalo E. Verenpainepotilas terveyskeskuksessa: hoidossa yhä parantamisen varaa. Suom Lääkäril 2001;56:269-74
9. Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001;19:S41-S48
10. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91, 318
11. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51
12. Mayer Jr O, Simon J, Heidrich J, et al. Educational level and risk profile of cardiac patients in the EUROASPIRE II substudy. J Epidemiol Community Health 2004;58:47-52
13. Rutledge T, Reis SE, Olson M, et al. Socioeconomic status variables predict cardiovascular disease risk factors and prospective mortality risk among women with chest pain. The WISE Study. Behav Modif 2003;27:54-67
14. Bachmann MO, Eachus J, Hopper CD, et al. Socio-economic inequalities in diabetes complications, control, attitudes and health service use: a cross-sectional study. Diabetic Med 2003;20:921-9
15. Marmot MG, McDowall ME. Mortality decline and widening social inequalities. Lancet 1986;2:274-6
16. Pekkanen J, Uutela A, Valkonen T, et al. Coronary risk factor levels: differences between educational groups in 1972-87 in eastern Finland. J Epidemiol Community Health 1995;49:144-9
17. Schneider S, Mohnen S, Schiltenwolf M. 'Are rich people healthier?' - representative epidemiological data on socioeconomic group-specific disease prevalences among adults in Germany. Dtsch Med Wochenschr 2006;131:1998-2003
18. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4
19. Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. Can J Cardiol 1997;13:914-20
20. Fincke BG, Miller DR, Spiro 3rd A. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med 1998;13:182-5
21. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997;95:1085-90
22. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. New Engl J Med 1998;339:1957-63
23. Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413-20
24. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000;160:2281-6
25. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. J Am Med Assoc 2003;289:2560-71
26. Martin DJ, Garske JP, Davis MK. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. Journal Consult Clin Psychol 2000;68:438-50
27. Neuwirth ZE. Physician empathy - should we care? Lancet 1997;350:606
28. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446-57[discussion 24-5]
29. Conlin PR, Gerth WC, Fox J, et al. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23:1999-2010
30. Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005;14:795-803
31. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75
32. Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens Suppl 2001;19:S41-S48
33. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91, 318
34. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51
35. Liberatos P, Link BG, Kelsey JL. The measurement of social class in epidemiology. Epidemiologic reviews 1988;10:87-121
36. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease: a review of the literature. Circulation 1993;88:1973-98
37. Helmert U, Herman B, Joeckel KH, et al. Social class and risk factors for coronary heart disease in the Federal Republic of Germany. Results of the baseline survey of the German Cardiovascular Prevention Study (GCP). J Epidemiol Community Health 1989;43:37-42
38. Helmert U, Mielck A, Classen E. Social inequities in cardiovascular disease risk factors in East and West Germany. Soc Sci Med 1992;35:1283-92
39. Marotta T, Viola S, Ferrara F, Ferrara LA. Improvement of cardiovascular risk profile in an elderly population of low social level: the ICON (Improving Cardiovascular risk profile in Older Neapolitans) study. J Hum Hypertens 2007;21:76-85
40. Colhoun HM, Hemingway H, Poulter NR. Socio-economic status and blood pressure: an overview analysis. J Hum Hypertens 1998;12:91-110
41. Krupa-Wojciechowska B, Zdrojewski T. Socio-economic factors in the management of hypertension: the Polish experience. J Hypertens 2004;22:661-2
42. Hypertension Detection and Follow-up Program Cooperative Group. Race, education and prevalence of hypertension. Am J Epidemiol 1977;106:351-61
43. Schneiderman MA. The proper size of a clinical trial: 'Grandma's Strudel' method. J New Drugs 1964;45:3-11
44. Brunner HR. Clinical efficacy and tolerability of olmesartan. Clin Ther 2004;26(Suppl A):A28-A32
45. Dusing R. Adherence to medical treatment. Dtsch Med Wochenschr 2006;131:H28-H30
46. Zdrojewski T, Pienkowski R, Szynkiewicz M, Krupa-Wojciechowska B. Have rapid socioeconomic changes influenced awareness of blood pressure in Poland? J Hum Hypertens 2001;15:247-53